Frederick et al. reported that tumor biopsies following BRAF ± MEK inhibitor combination therapy exhibited an increase in T-cell exhaustion markers (TIM3 and PD1) and downregulation of both melanoma antigen presentation and CD8+ T cell infiltration upon progression on BRAF inhibitors [41]. This evidence concerns the gene MAP2K7 and neoplasm.